Literature DB >> 27698496

Surrogate Markers and Drug Approvals.

Danial E Baker.   

Abstract

Year:  2016        PMID： 27698496      PMCID： PMC5030868          DOI： 10.1310/hpj5108-611

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


× No keyword cloud information.
  2 in total

1.  Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.

Authors:  Brendan M Everett; Robert J Smith; William R Hiatt
Journal:  N Engl J Med       Date:  2015-10-07       Impact factor: 91.245

2.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245
  2 in total
  1 in total

Review 1.  Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape.

Authors:  Mariya Gromova; Annegret Vaggelas; Gabriele Dallmann; Diane Seimetz
Journal:  Biomark Insights       Date:  2020-12-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.